Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial

NCT03886779 is registered in ClinicalTrials.gov with Silverstein Eye Centers as lead sponsor.

NCT NCT03886779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03886779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial
Lead sponsor
Silverstein Eye Centers
Phase
Phase 4
Overall status
Completed
Start date
October 30, 2013
Completion date
March 31, 2019
Enrollment
57 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

treatment of ocular inflammation associated with cataract surgery